Business Wire

Experian Selected as a Leading Provider of Fraud Detection and Prevention

Share

Experian was named one of the established leaders in fraud detection and prevention in Juniper Research’s Online Payment Fraud Deep Dive Strategy & Competition 2021-2025. The report looks at the continuing growth in online payment and the vulnerability it has caused for online fraud and identity theft.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210713005278/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

The Juniper Research Online Payment Fraud Report 2021 highlights how the digital payments boom has created vast opportunities for fraud. (Graphic: Business Wire)

“As businesses transformed their operations to accommodate the rapidly growing volume of digital transactions, consumer expectations for easy and secure interactions increased at an even faster pace,” said David Britton, Experian’s vice president of industry solutions for Global Identity & Fraud. “Businesses must find ways to continually improve the customer experience, while at the same time, protecting consumer identities and information.”

The Juniper report, which takes a deep dive into emerging threats, segment analysis and market forecasts, also looks at the online payment fraud competitor analysis. Juniper scored Experian high for their marketing and branding strength, service range and features, financial performance in the sector, experience in sector, operations and global reach, partnerships, creativity and innovation, and future business prospects.

According to Juniper Research, “Experian continues to invest into its fraud detection and prevention solution and uses its vast array of customer data to deliver an effective set of solutions across the entire consumer journey, from onboarding, through account management/account takeover and transaction risk mitigation.” The report highlights the Experian CrossCore platform noting, “Experian leverages a combination of proprietary solutions and partner capabilities and data – integrated into its CrossCore platform – where it leverages a robust machine learning approach that takes into account these dynamic sources of data.”

All of Experian’s fraud detection and prevention services are available through Experian’s CrossCore partner ecosystem. Combining advanced analytics, rich data assets, identity insights and fraud prevention capabilities, businesses can connect any new or existing tools and systems in one place, whether it be Experian’s, Experian partners’ or its own. With its built-in strategy design and enhanced workflow, fraud and compliance teams have more control to quickly adjust strategies based on evolving threats and business needs, which helps to improve efficiency and reduce operational costs. Learn more about the CrossCore platform.

About Experian
Experian is the world’s leading global information services company. During life’s big moments — from buying a home or a car to sending a child to college to growing a business by connecting with new customers — we empower consumers and our clients to manage their data with confidence. We help individuals to take financial control and access financial services, businesses to make smarter decisions and thrive, lenders to lend more responsibly, and organizations to prevent identity fraud and crime.

We have 17,800 people operating across 44 countries, and every day we’re investing in new technologies, talented people and innovation to help all our clients maximize every opportunity. We are listed on the London Stock Exchange (EXPN) and are a constituent of the FTSE 100 Index.

Learn more at www.experianplc.com, visit our global insights content hub at our global news blog for the latest news and insights from the Group.

Experian and the Experian trademarks used herein are trademarks or registered trademarks of Experian and its affiliates. Other product and company names mentioned herein are the property of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Kristie Galvani
Rubenstein Public Relations
1 212 805 3005
kgalvani@rubensteinpr.com

Jordan Takeyama
Experian Public Relations

1 714 830 7561
jordan.takeyama@experian.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Posiflex to Showcase AI-Powered Retail Innovation at EuroShop 202619.1.2026 10:57:00 EET | Press release

Posiflex Technology, Inc., a global leader in Point of Sale (POS) systems and Online-to-Offline (O2O) solutions, will present its latest portfolio of AI-powered retail innovations at EuroShop 2026, taking place from February 22 to 26, 2026 at Messe Düsseldorf, Germany. Celebrating the 60th edition of the world’s leading retail trade fair, Posiflex will demonstrate how AI-enabled technologies and scenario-driven system design can address the evolving demands of modern retail environments, spanning self-checkout, AI recognition, contactless transactions, kitchen operations, and next-generation self-service. Visitors are invited to explore these solutions at Hall 6, Booth C42, and discover how Posiflex supports retailers in building agile, future-ready business models. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118544299/en/ Posiflex presents end-to-end solutions that redefine the modern retail journey AI-Powered Smart S

Alta Semper Signs Definitive Agreements to Acquire a Majority Stake in Nature’s Rule, a MENA-Focused Leader in Dietary Supplements and Sports Nutrition19.1.2026 10:13:00 EET | Press release

Alta Semper, a London-based private equity firm focused on healthcare and consumer investments across growth markets, today announced that it has signed definitive agreements to acquire a majority stake in Nature’s Rule, a leading sports nutrition and dietary supplements company headquartered in the UAE, with an established manufacturing presence in Egypt. The acquisition is a majority investment in Prowell Holding, the parent company of Nature’s Rule, the operator of the largest fully dedicated sports nutrition and dietary supplements manufacturing facility in MENA. The company’s infrastructure and in-house R&D capabilities support a portfolio of private-label clients and proprietary brands, including Redrex, its flagship, market-leading sports nutrition brand developed in collaboration with global bodybuilding icon Mamdouh Elssbiay (“Big Ramy”). The founders will retain a significant stake and continue to lead the business. The partnership will execute a focused value-creation plan t

The UK Chooses Bridge Over Troubled Water as the Nation’s Favourite Song of Hope in Solidarity With Refugees19.1.2026 10:00:00 EET | Press release

Simon and Garfunkel’s Bridge Over Troubled Water has been votedas the UK’s number one #HopeHit ― as part of UK for UNHCR’s ‘Hope on Repeat’ campaign, raising awareness of the hardships facing refugees across the globe this winter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260119165712/en/ Simon & Garfunkel's Bridge Over Troubled Water voted the UK's number one #HopeHit With 10% of the public vote, Bridge Over Troubled Water emerged as the UK’s most popular #HopeHit. Since November, the UN Refugee Agency’s national charity partner has invited people to nominate their #HopeHits - the tunes that connect us and warm our hearts as the weather gets cold. The top hit is announced today, Blue Monday, to help people get through the most depressing day of the year. The 1970 chart topper held off stiff competition from Stand By Me by Ben E King with 5.7% of the vote and Imagine by John Lennon with 5.3%. Hope on Repeat in support o

Prodalim Expands SOLOS Capabilities with New Dealcoholization Site in Spain19.1.2026 09:33:00 EET | Press release

Prodalim, a global leader in juice and specialty ingredients solutions, announced today the expansion of its SOLOS division with the opening of a dedicated dealcoholization and aroma recovery site in Valencia, Spain. The new facility is fully operational and strengthens Prodalim’s ability to support the rapidly growing no- and low-alcohol (NoLo) beverage market across Europe. During the coming months, an additional SOLOS site in California is planned to be inaugurated, further expanding overall capacity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260118626123/en/ Inauguration of the SOLOS Valencia Site for Advanced NoLo Solutions The global NoLo category continues to expand, driven by consumer demand for mindful drinking and healthier lifestyle choices. Industry forecasts estimate the NoLo global market at approximately USD 25 billion in 2025, with expected annual growth of 8–10% as the category expands across beers, win

ENHERTU ® Plus Pertuzumab Type II Variation Application Validated in the EU as First-Line Treatment of Patients with HER2 Positive Metastatic Breast Cancer19.1.2026 09:30:00 EET | Press release

The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) in combination with pertuzumab for the first-line treatment of adult patients with unresectable or metastatic HER2 positive breast cancer. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast09 phase 3 trial presentedduring a speciallate-breaking oral session at the 2025 American Society of Clinical Oncology (#ASCO25) Annual Meeting and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU in combination with pertuz

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye